Germany’s Added Benefit System May Gain Credibility As It Lauds Zytiga And Cans Trajenta
Decisions by Germany’s drug benefit assessor, IQWiG, to recommend novel prostate cancer treatment Zytiga and reject me-too diabetes treatment Trajenta may allay confusion over just how well the country’s new added value assessment process is working
You may also be interested in...
Comparator issues have wrecked reimbursement prospects for the second time for Boehringer/Lilly’s diabetes drug Trajenta in Germany as authorities dispute the utility of a study published in The Lancet comparing the product to the sulphonylurea glimepiride.
Germany's Boehringer Ingelheim returns to sales growth and looks to Phase III hepatitis C and oncology products to provide long-term growth.
A new chairman will take the helm of Germany's G-BA panel at a pivotal time for AMNOG implementation; the European Medicines Agency issues guidances in oncology drug development and genotoxicity; more regulatory updates.